Preoperative management of operable cT3 cN1 luminal breast cancer: Upfront neoadjuvant chemotherapy

Share :
Published: 27 Jan 2020
Views: 555
Prof Joseph Gligorov - Paris-Sorbonne University, Paris, France

Prof Joseph Gligorov speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the upfront use of neoadjuvant chemotherapy in operable cT3 cN1 luminal breast cancer in the preoperative phase.

He explains the three different indications of using neoadjuvant chemotherapy and believes that there is a place for neoadjuvant chemotherapy for patients with high-grade, large and less endocrine-sensitive tumours.